Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "6-Mercaptopurine"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia
Eun Sang Yi, Young Bae Choi, Rihwa Choi, Na Hee Lee, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Soo-Youn Lee, Hong Hoe Koo
Cancer Res Treat. 2018;50(3):872-882.   Published online September 13, 2017
DOI: https://doi.org/10.4143/crt.2017.283
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to identify the impact of NUDT15 variants on thiopurine intolerance and 6-thioguanine nucleotide (6-TGN) levels in Korean children with acute lymphoblastic leukemia (ALL).
Materials and Methods
Genotyping of NUDT15 was tested in 258 patients with ALL registered at Samsung Medical Center. Patients were classified into normal-activity (wild-type), intermediate-activity (heterozygous variant), and low-activity groups (homozygous or compound heterozygous variant). Clinical and laboratory features during the first year of maintenance therapy were investigated.
Results
A total of 182 patients were included in the final analysis. There were five (2.7%), 46 (25.3%), and 131 (72.0%) patients in low-, intermediate-, and normal-activity groups, respectively. The lowest 6-mercaptopurine (6-MP) dose (mg/m2/day) was administered to the low-activity group (low-activity group 7.5 vs. intermediate-activity group 24.4 vs. normalactivity group 31.1, p < 0.01) from three months to a year after beginning maintenance therapy. The low-activity group experienced the longest duration of therapy interruption during the first year (low-activity group 169 days vs. intermediate-activity group 30 days vs. normal-activity group 16 days, p < 0.01). They also showed the lowest blood cell counts and had a longer duration of leukopenia (low-activity group 131 days vs. intermediate-activity group 92 days vs. normal-activity group 59 days, p < 0.01). 6-TGN level and its ratio to 6-MP dose were lowest in the low-activity group.
Conclusion
NUDT15 variants cause hematopoietic toxicity with low 6-TGN levels. NUDT15 genotyping should be conducted before administering thiopurine, and dose adjustments require caution regardless of 6-TGN levels.

Citations

Citations to this article as recorded by  
  • The frequency of NUDT15 rs116855232 and its impact on mercaptopurine-induced toxicity in Syrian children with acute lymphoblastic leukemia
    Muhammad Muhammad, Maher Saifo, Majd Aljamali, Mousa Alali, Khaled M. Ghanem
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Editorial Response to the Letter Relating to our Article “Predicting Adverse Events to Thiopurines in IBD: Are We a Step Closer?”
    Mohmmed Tauseef Sharip, Miles Parkes, Sreedhar Subramanian
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant
    Navya Gupta, Latha Sneha Magatha, Dhaarani Jayaraman, Julius Xavier Scott, Sharon Benita Antony, Teena Koshy
    Journal of Oncology Pharmacy Practice.2023; 29(4): 999.     CrossRef
  • Density functional study of transition metal (Fe,Co,Ni)‐doped C60 fullerenes as 6‐thioguanine delivery system
    ShiQuan Wu, Li Li, QiQi Liang, HuaXu Gao, DeYuan Hu, TianYu Tang, Yanlin Tang
    Applied Organometallic Chemistry.2023;[Epub]     CrossRef
  • The influence of NUDT15 variants on 6-mercaptopurine-induced neutropenia in Vietnamese pediatric acute lymphoblastic leukemia
    Mai-Lan Nguyen, Anh Vu Hoang, Bich Tram Duong, Nguyen The Nguyen Phung
    Human Genetics and Genomics Advances.2023; 4(2): 100183.     CrossRef
  • NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China
    XiaoXia Wei, Jing Zhuang, Na Li, Bin Zheng, Hong Sun, JiaQin Cai, Xuhui Huang, Guifeng Zhang, Jie Zhuang
    International Journal of Hematology.2022; 115(2): 278.     CrossRef
  • NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine
    Kanyarat Khaeso, Patcharee Komvilaisak, Su-on Chainansamit, Nontaya Nakkam, Kunanya Suwannaying, Pitchayanan Kuwatjanakul, Keiko Hikino, Areerat Dornsena, Sirimas Kanjanawart, Napat Laoaroon, Suda Vannaprasaht, Takeshi Taketani, Wichittra Tassaneeyakul
    Drug Metabolism and Pharmacokinetics.2022; 43: 100436.     CrossRef
  • NUDT15 Genetic Variants in Chinese Han, Uighur, Kirghiz, and Dai Nationalities
    Fang Zhang, Gulbanur Amat, Yanjing Tang, Ru Chen, Xin Tian, Wenting Hu, Changcheng Chen, Shuhong Shen, Yangyang Xie
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population
    Kok-Siong Poon, Izz Irfan B. Imran, Silvester Kheng-Han Chew, Patrice Tan, Karen Mei-Ling Tan
    BMC Research Notes.2022;[Epub]     CrossRef
  • NUDT15Genotyping in Thiopurine Drug Therapy
    Jong Kwon Lee, Rihwa Choi, Soo-Youn Lee
    Laboratory Medicine Online.2022; 12(4): 217.     CrossRef
  • The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia
    Jae Min Lee, Ye Jee Shim, Do-Hoon Kim, Nani Jung, Jung-Sook Ha
    Children.2021; 8(3): 224.     CrossRef
  • Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy
    Abdelbaset A. Elzagallaai, Bruce C. Carleton, Michael J. Rieder
    Annual Review of Pharmacology and Toxicology.2021; 61(1): 679.     CrossRef
  • DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes
    Hee Young Ju, Ji Won Lee, Hee Won Cho, Ju Kyung Hyun, Youngeun Ma, Eun Sang Yi, Keon Hee Yoo, Ki Woong Sung, Rihwa Choi, Hong Hoe Koo, Soo-Youn Lee, A. M. Abd El-Aty
    PLOS ONE.2021; 16(1): e0245667.     CrossRef
  • NUDT15: A bench to bedside success story
    Ann M. Moyer
    Clinical Biochemistry.2021; 92: 1.     CrossRef
  • Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study
    Zhao-Yang Chen, Yang-Hui Zhu, Ling-Yan Zhou, Wei-Qiao Shi, Zhou Qin, Bin Wu, Yu Yan, Yu-Wen Pei, Ning-Ning Chao, Rui Zhang, Mi-Ye Wang, Ze-Hao Su, Xiao-Jun Lu, Zhi-Yao He, Ting Xu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China
    Gangling Pu, Yali Wang, Shaoqin Duan, Jingpei Chen, Chunhui Yang, Tingting Cui, Chunlian Fang, Yan Zhou, Han Zhang, Xin Tian
    Pediatrics International.2021; 63(7): 790.     CrossRef
  • Significance of TPMT and NUDT15 variants in 6-mercaptopurine metabolism in acute lymphoblastic leukaemia/lymphoma patients
    E. S. Kotova, O. A. Gavrilina, A. B. Sudarikov
    Russian journal of hematology and transfusiology.2021; 66(2): 253.     CrossRef
  • NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy
    Aswin Anand Pai, Ajith Mohan, Esther Sathya Bama Benjamin, Raveen Stephen Stallon Illangeswaran, Infencia Xavier Raj, Nancy Beryl Janet, Arun Kumar Arunachalam, ML Kavitha, Uday Kulkarni, Anup J Devasia, NA Fouzia, Aby Abraham, Alok Srivastava, Biju Georg
    Pharmacogenomics and Personalized Medicine.2021; Volume 14: 1303.     CrossRef
  • Reducing risk in thiopurine therapy
    Anthony M. Marinaki, Monica Arenas-Hernandez
    Xenobiotica.2020; 50(1): 101.     CrossRef
  • Precision therapy of 6‐mercaptopurine in Chinese children with acute lymphoblastic leukaemia
    Yue Zhou, Li Wang, Xiao‐Ying Zhai, Li Wen, Fang Tang, Fan Yang, Xi‐Ting Liu, Lei Dong, Li‐Juan Zhi, Hai‐Yan Shi, Guo‐Xiang Hao, Yi Zheng, Evelyne Jacqz‐Aigrain, Tian‐You Wang, Wei Zhao
    British Journal of Clinical Pharmacology.2020; 86(8): 1519.     CrossRef
  • NUDT15 Genetic Variants are Related to Thiopurine-Induced Neutropenia in Thai Children with Acute Lymphoblastic Leukemia
    Apichaya Puangpetch, Rawiporn Tiyasirichokchai, Samart Pakakasama, Supaporn Wiwattanakul, Usanarat Anurathapan, Suradej Hongeng, Chonlaphat Sukasem
    Pharmacogenomics.2020; 21(6): 403.     CrossRef
  • Association of NUDT15 c.415C>T and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia
    Sunitha Kodidela, Patchava Dorababu, Dimpal N. Thakkar, Biswajit Dubashi, Rajan Sundaram, Niveditha Muralidharan, Ravi Prasad Nidanapu, Anil Aribandi, Suresh Chandra Pradhan, Chakradhara Rao Satyanarayana Uppugunduri
    Genes.2020; 11(6): 594.     CrossRef
  • Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia
    Shaik Mohammad Naushad, Patchava Dorababu, Yedluri Rupasree, Addepalli Pavani, Digumarti Raghunadharao, Tajamul Hussain, Salman A. Alrokayan, Vijay Kumar Kutala
    Cancer Chemotherapy and Pharmacology.2019; 83(5): 875.     CrossRef
  • Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia
    Rihwa Choi, Insuk Sohn, Min‐Ji Kim, Hye In Woo, Ji Won Lee, Youngeun Ma, Eun Sang Yi, Hong Hoe Koo, Soo‐Youn Lee
    British Journal of Clinical Pharmacology.2019; 85(7): 1585.     CrossRef
  • Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients
    Xia Zhu, Kang Chao, Miao Li, Wen Xie, Hong Zheng, Jin-Xin Zhang, Pin-Jin Hu, Min Huang, Xiang Gao, Xue-Ding Wang
    World Journal of Gastroenterology.2019; 25(38): 5850.     CrossRef
  • Homozygous mutation in NUDT15 in childhood acute lymphoblastic leukemia with increased susceptibility to mercaptopurine toxicity: A case report
    Juan Cheng, Hao Zhang, Hai‑Zhen Ma, Juan Li
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping
    Yoichi Kakuta, Yoshitaka Kinouchi, Tooru Shimosegawa
    Journal of Gastroenterology.2018; 53(2): 172.     CrossRef
  • 10,406 View
  • 390 Download
  • 29 Web of Science
  • 27 Crossref
Close layer
APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
Hyery Kim, Heewon Seo, Yoomi Park, Byung-Joo Min, Myung-Eui Seo, Kyung Duk Park, Hee Young Shin, Ju Han Kim, Hyoung Jin Kang
Cancer Res Treat. 2018;50(3):823-834.   Published online September 4, 2017
DOI: https://doi.org/10.4143/crt.2017.351
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mercaptopurine (MP) is one of the main chemotherapeutics for acute lymphoblastic leukemia (ALL). To improve treatment outcomes, constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. We performed two-stage analyses to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients.
Materials and Methods
Targeted sequencing of 40 patients who exhibited definite MP intolerance was conducted using a novel panel of 211 pharmacogenetic-related genes, and subsequent analysis was performed with 185 patients.
Results
Using bioinformatics tools and genetic data, four functionally interesting variants were selected (ABCC4, APEX1, CYP1A1, and CYP4F2). Including four variants, 23 variants in 12 genes potentially linked to MP adverse reactions were selected as final candidates for subsequent analysis in 185 patients. Ultimately, a variant allele in APEX1 rs2307486was found to be strongly associated with MP-induced neutropenia that occurred within 28 days of initiating MP (odds ratio, 3.44; p=0.02). Moreover, the cumulative incidence of MP-related neutropenia was significantly higher in patients with APEX1 rs2307486 variants, as GG genotypes were associated with the highest cumulative incidence (p < 0.01). NUDT15 rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01).
Conclusion
We have identified that APEX1 rs2307486 variants conferred an increased risk of MP-related early onset neutropenia. APEX1 and NUDT15 both contribute to cell protection from DNA damage or misincorporation, so alleles that impair the function of either gene may affect MP sensitivities, thereby inducing MP-related neutropenia.

Citations

Citations to this article as recorded by  
  • Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response
    Ashwin Kamath, Suresh Kumar Srinivasamurthy, Mukta N. Chowta, Sheetal D. Ullal, Youssef Daali, Uppugunduri S. Chakradhara Rao
    Pharmaceuticals.2022; 15(8): 990.     CrossRef
  • The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia
    Jae Min Lee, Ye Jee Shim, Do-Hoon Kim, Nani Jung, Jung-Sook Ha
    Children.2021; 8(3): 224.     CrossRef
  • Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT
    Hyery Kim, Seungwon You, Yoomi Park, Jung Yoon Choi, Youngeun Ma, Kyung Tak Hong, Kyung-Nam Koh, Sunmin Yun, Kye Hwa Lee, Hee Young Shin, Suehyun Lee, Keon Hee Yoo, Ho Joon Im, Hyoung Jin Kang, Ju Han Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China
    Gangling Pu, Yali Wang, Shaoqin Duan, Jingpei Chen, Chunhui Yang, Tingting Cui, Chunlian Fang, Yan Zhou, Han Zhang, Xin Tian
    Pediatrics International.2021; 63(7): 790.     CrossRef
  • A Dual Face of APE1 in the Maintenance of Genetic Stability in Monocytes: An Overview of the Current Status and Future Perspectives
    Gabriela Betlej, Ewelina Bator, Antoni Pyrkosz, Aleksandra Kwiatkowska
    Genes.2020; 11(6): 643.     CrossRef
  • Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT
    Yoomi Park, Hyery Kim, Heewon Seo, Jung Yoon Choi, Youngeun Ma, Sunmin Yun, Byung-Joo Min, Myung-Eui Seo, Keon Hee Yoo, Hyoung Jin Kang, Ho Joon Im, Ju Han Kim
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology
    Emma C. Bernsen, Melanie M. Hagleitner, Theodorus W. Kouwenberg, Lidwien M. Hanff
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens: a single-center analysis
    Ho Jung Choi, Juhee Shin, Sunghan Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
    BLOOD RESEARCH.2020; 55(4): 262.     CrossRef
  • NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia
    Eun Sang Yi, Young Bae Choi, Rihwa Choi, Na Hee Lee, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Soo-Youn Lee, Hong Hoe Koo
    Cancer Research and Treatment.2018; 50(3): 872.     CrossRef
  • 23,824 View
  • 333 Download
  • 12 Web of Science
  • 9 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP